| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Enanta Pharmaceuticals Inc (NASDAQ: ENTA)
ENTA Technical Analysis
5
| As on 9th Jun 2023 ENTA STOCK Price closed @ 25.99 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 57.76 & Strong Sell for SHORT-TERM with Stoploss of 66.13 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ENTASTOCK Price
| Open | 26.20 | Change | Price | % |
| High | 26.91 | 1 Day | -0.12 | -0.46 |
| Low | 25.90 | 1 Week | 2.51 | 10.69 |
| Close | 25.99 | 1 Month | -7.98 | -23.49 |
| Volume | 143100 | 1 Year | -51.40 | -66.42 |
| 52 Week High 78.97 | 52 Week Low 23.48 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ENTA Daily Charts |
ENTA Intraday Charts |
Whats New @ Bazaartrend |
ENTA Free Analysis |
|
|
ENTA Important Levels Intraday
| RESISTANCE | 27.94 |
| RESISTANCE | 27.31 |
| RESISTANCE | 26.93 |
| RESISTANCE | 26.54 |
| SUPPORT | 25.44 |
| SUPPORT | 25.05 |
| SUPPORT | 24.67 |
| SUPPORT | 24.04 |
ENTA Forecast April 2024
| 4th UP Forecast | 62.31 |
| 3rd UP Forecast | 50.66 |
| 2nd UP Forecast | 43.46 |
| 1st UP Forecast | 36.26 |
| 1st DOWN Forecast | 15.72 |
| 2nd DOWN Forecast | 8.52 |
| 3rd DOWN Forecast | 1.32 |
| 4th DOWN Forecast | -10.33 |
ENTA Weekly Forecast
| 4th UP Forecast | 41.10 |
| 3rd UP Forecast | 36.25 |
| 2nd UP Forecast | 33.26 |
| 1st UP Forecast | 30.26 |
| 1st DOWN Forecast | 21.72 |
| 2nd DOWN Forecast | 18.72 |
| 3rd DOWN Forecast | 15.73 |
| 4th DOWN Forecast | 10.88 |
ENTA Forecast2024
| 4th UP Forecast | 135.25 |
| 3rd UP Forecast | 100.21 |
| 2nd UP Forecast | 78.55 |
| 1st UP Forecast | 56.89 |
| 1st DOWN Forecast | -4.91 |
| 2nd DOWN Forecast | -26.57 |
| 3rd DOWN Forecast | -48.23 |
| 4th DOWN Forecast | -83.27 |
Enanta Pharmaceuticals Inc ( NASDAQ USA Symbol : ENTA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ENTA Business Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts. Address: 500 Arsenal Street, Watertown, MA, United States, 02472
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service